最新观点
Insights From Our Experts
Articles
BLOG: Not So Rare… The True Impact of Rare Diseases
Posted by
Dr. Richard Stefanacci on 3 月 15, 20213/15/21
Rare disease treatments seem to be everywhere today. This is true despite the fact that to be considered a rare disease, fewer than 200,000 patients are affected — and for ultra-rare, fewer than 7,000 patients are affected. This definition was created by Congress in the Orphan Drug Act of 1983. Rare diseases became known as orphan…
Webinar: Drug Pricing and Reporting Regulatory Updates Part 2
In Part 2 of our Drug Pricing and Reporting Regulatory Updates webinar, EVERSANA revenue experts take a look at the Final Rule, which was released by the Centers for Medicare and Medicaid Services in December 2020.…
Webinar: Drug Pricing and Reporting Regulatory Updates Part 1
Pharmaceutical companies in the U.S. are navigating President Biden’s new administration and legislative changes that are affecting pricing and regulatory actions. One of these changes includes the regulatory freeze ordered for actions made in the final two months of…
Watch Now: PharmaVOICE Panel on Next Gen Patient Services Models
The Future of Data-Driven Patient Support Is Now The use of health data technologies and analytics in the life sciences industry continues to evolve, but many manufacturers are still crawling around in the dark. With limited…
Global Shifts in Legislative Regulation Are Forcing Pharma Back to the Drawing Board : February 2021
In only a short time this year, the pharmaceutical industry is witnessing new regulations and legislative changes going into effect globally – and the growing pains are setting in. Between the new U.S. administration and E.U. Pharmaceutical Strategy, governmental entities…
BLOG: Population Health Leadership
Posted by
Dr. Richard Stefanacci on 2 月 24, 20212/24/21
“Population health” is the result of pushing health systems to be clinically and financially responsible for their communities. This is a significant shift from simply being focused on the volume of services delivered within the hospital. The focus on population health represents a movement for pharma from…
Leveraging RWE to Enhance Experiences Across the Patient Journey
In a tech-driven healthcare ecosystem in which patients are engaged consumers, product value is contingent on treatment outcomes and patient success. With digital tools and resources at their fingertips, today’s patient is empowered to make informed…
Reinventing Launch: The Gold Standard Of Drug Commercialization
In a world that is rapidly changing, we must evolve beyond traditional strategies to create true impact for patients. EVERSANA's complete end-to-end commercialization model enables manufacturers to bring their drug to market at a fraction of…
The Crush: How Covid-19 Is Impacting Mature Brand Revenue & Long-Term Value
The impact of COVID is reverberating across all aspects of society and business. In the healthcare industry, hundreds of thousands of patients are not getting proper access to and utilization of therapies that can improve their…
Reimbursement May Be on the Way for Remote Therapeutic Monitoring
The American Medical Association (AMA) manages the procedure code set that physicians and other healthcare professionals use to identify the services for which they bill. These codes are commonly known as the CPT® code set, which…